Investors in Apeloa PharmaceuticalLtd (SZSE:000739) Have Seen Respectable Returns of 69% Over the Past Five Years
Investors in Apeloa PharmaceuticalLtd (SZSE:000739) Have Seen Respectable Returns of 69% Over the Past Five Years
When we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is one path to excess returns. For example, the Apeloa Pharmaceutical Co.,Ltd (SZSE:000739) share price is up 61% in the last 5 years, clearly besting the market return of around 17% (ignoring dividends).
当我们投资时,我们通常是在寻找表现超过市场平均水平的股票。收购被低估的企业是获得超额回报的一种途径。例如,Apeloa Pharmaceutical Co., Ltd(深圳证券交易所股票代码:000739)的股价在过去5年中上涨了61%,显然超过了约17%的市场回报率(不计股息)。
With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.
考虑到这一点,值得一看公司的基本面是否是长期业绩的驱动力,或者是否存在一些差异。
There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).
不可否认,市场有时是有效的,但价格并不总是能反映潜在的业务表现。研究市场情绪如何随着时间的推移而变化的一种方法是研究公司股价与其每股收益(EPS)之间的相互作用。
During five years of share price growth, Apeloa PharmaceuticalLtd achieved compound earnings per share (EPS) growth of 21% per year. The EPS growth is more impressive than the yearly share price gain of 10% over the same period. So one could conclude that the broader market has become more cautious towards the stock.
在五年的股价增长中,Apeloa PharmaceuticalLTD实现了每年21%的复合每股收益(EPS)增长。每股收益的增长比同期10%的年度股价增长更令人印象深刻。因此,人们可以得出结论,整个市场对该股变得更加谨慎。
The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers).
该公司的每股收益(随着时间的推移)如下图所示(点击查看确切数字)。
![earnings-per-share-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240521/0-bb039ca0b58ba9b8d1392e2b2935f3d8-0-bf629094a3b379ba116093a5fb461ca5.png/big)
We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. But while CEO remuneration is always worth checking, the really important question is whether the company can grow earnings going forward. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..
我们很高兴地向大家报告,首席执行官的薪水比资本相似公司的大多数首席执行官都要适中。但是,尽管首席执行官的薪酬总是值得检查的,但真正重要的问题是公司未来能否增加收益。在买入或卖出股票之前,我们始终建议仔细研究历史增长趋势,可在此处查阅。
What About Dividends?
分红呢?
When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. We note that for Apeloa PharmaceuticalLtd the TSR over the last 5 years was 69%, which is better than the share price return mentioned above. The dividends paid by the company have thusly boosted the total shareholder return.
在考虑投资回报时,重要的是要考虑两者之间的区别 股东总回报 (TSR) 和 股价回报。尽管股价回报率仅反映股价的变化,但股东总回报率包括股息的价值(假设已进行再投资)以及任何折扣融资或分拆的收益。因此,对于支付丰厚股息的公司来说,股东总回报率通常远高于股价回报率。我们注意到,Apeloa PharmaceuticalLTD在过去5年的股东总回报率为69%,好于上述股价回报率。因此,该公司支付的股息提高了股息 总 股东回报。
A Different Perspective
不同的视角
We regret to report that Apeloa PharmaceuticalLtd shareholders are down 19% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 8.7%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 11%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Apeloa PharmaceuticalLtd better, we need to consider many other factors. To that end, you should be aware of the 1 warning sign we've spotted with Apeloa PharmaceuticalLtd .
我们遗憾地报告,Apeloa PharmaceuticalLTD的股东今年下跌了19%(甚至包括股息)。不幸的是,这比整个市场8.7%的跌幅还要严重。但是,可能只是股价受到了更广泛的市场紧张情绪的影响。如果有很好的机会,可能值得关注基本面。长期投资者不会那么沮丧,因为他们本可以在五年内每年赚11%。如果基本面数据继续显示长期可持续增长,那么当前的抛售可能是一个值得考虑的机会。长期跟踪股价表现总是很有意思的。但是,要更好地了解Apeloa PharmaceuticalLTD,我们需要考虑许多其他因素。为此,你应该注意我们在Apeloa PharmaceuticalLTD身上发现的1个警告信号。
But note: Apeloa PharmaceuticalLtd may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但请注意:Apeloa PharmaceuticalLTD可能不是最值得购买的股票。因此,来看看这份过去盈利增长(以及进一步增长预测)的有趣公司的免费清单。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文引用的市场回报反映了目前在中国交易所交易的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。